LONDON, Jan. 15, 2015 /PRNewswire/ -- Report Details
Biosimilar drugs - discover trends and areas with highest revenue potential
Do you want to find the sales potential of biosimilars? Visiongain's updated report gives you revenue predictions for those biological drugs from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities and discussions of prospects.
In that work you see forecasted sales to 2023 at overall world market, submarket, molecule and national level. You also assess emerging trends, technologies and expected products.
You see what shapes that industry and find its revenue prospects
Discover, then, what the future holds for biosimilars (follow-on biologics, follow-on protein products). Read on to scan features of that industry and see what its future market could be worth.
Forecasts and other analyses show you the best commercial areas
In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. There you assess quantitative and qualitative analysis, business news, outlooks and developments (R&D). You also gain 113 tables, 66 charts and two research interviews.
Many opportunities exist for those competitors of original biological drugs (biologics). You discover areas most likely to prosper. Finding data you need has just got easier.
The following sections show how you benefit from the new analysis.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market for biosimilars and related agents, our work shows forecasts from 2013 to 2023 for its individual submarkets:
• Monoclonal antibodies (mAbs)
• Insulins - with sub forecasts for human insulin, fast-acting and long-acting analogues
• Interferons - with sub forecasts for alpha and beta interferon
• Erythropoietin (EPO)
• Follicle stimulating hormone (FSH).
The new report shows you revenue potentials of those biopharmaceuticals, helping you find opportunities to develop your business.
Also our investigation discusses what stimulates and restrains sales of those subsequent entry biologics. There you explore that industry, seeing what products can achieve the most success.
Discover sales forecasts for prominent therapeutic molecules
Our study forecasts revenues of prominent biosimilar agents at molecular level:
There you discover how high sales can go, to 2023, with individual forecasts. You see what's happening, understanding trends, competition, challenges and opportunities.
Our study also divides its overall world forecast into those for geographical regions.
Leading national markets - where will highest revenue growth occur?
Developments worldwide will influence that follow-on biologics market, especially rising demand in emerging countries - e.g. China, India and South Korea. See how and where.
Our analyses show you individual revenue forecasts to 2023 for twelve national markets and one regional block:
• The US
• The EU and its leading countries - Germany, France, the UK, Italy and Spain
• The BRIC countries - Brazil, Russia, India and China
• South Korea.
There you discover progress and outlooks. You assess the biosimilar industry's future - hear about developments and find their significance. Our work explains, exploring crucial issues.
What affects that biopharma industry and market?
The new report discusses issues and events affecting that industry and market from 2013, including these developments:
• Considerations for developing biosimilars
• Guidelines from the FDA expected in 2013
• Other regulations - including EMA and MHLW - with their effects on producers
• Challenges in developing biosimilar mAbs
Download the full report: https://www.reportbuyer.com/product/2368462/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48